While anti-VEGF therapies seem to be generally safe, the long-term consequences remain uncertain [4]. Given the increasing incidence of diabetes mellitus and, consequently DR, coupled with the substantial burden associated with current DR treatments, it becomes imperative to shift attention toward other contributory molecules and the development of novel targeted therapies to fight vision loss [1,5]. Here, VEGFA is linked to diabetes mellitus.